<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00882206</url>
  </required_header>
  <id_info>
    <org_study_id>2008LS112</org_study_id>
    <secondary_id>0810M50401</secondary_id>
    <secondary_id>MT2008-29R</secondary_id>
    <nct_id>NCT00882206</nct_id>
  </id_info>
  <brief_title>Pre-reinductive Decitabine and Vorinostat in Relapsed Lymphoblastic Lymphoma or Acute Lymphoblastic Leukemia</brief_title>
  <official_title>A Therapeutic Trial of Decitabine and Vorinostat in Combination With Chemotherapy (Vincristine, Prednisone, Doxorubicin and PEG-Asparaginase) for Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Masonic Cancer Center, University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Masonic Cancer Center, University of Minnesota</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer
      cells, either by killing the cells or by stopping them from dividing. Decitabine and
      vorinostat may alter the cancer cells by reversing the cancer pathways needed for cell
      growth. Giving more than one drug (combination chemotherapy) together with decitabine and
      vorinostat may kill more cancer cells than with chemotherapy alone.

      PURPOSE: This phase II trial is studying how well giving decitabine and vorinostat together
      with combination chemotherapy works in treating patients with acute lymphoblastic leukemia or
      lymphoblastic lymphoma that has relapsed or not responded to treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Patients undergo blood and bone marrow sample collection at baseline, on day 5, Day 19
           and at the end of study treatment for correlative laboratory studies. Samples are
           analyzed for hypermethylation at diagnosis and demethylation post-exposure with
           decitabine and vorinostat using LINE methylation.

      OUTLINE:

      Patients receive decitabine IV over 1 hour and oral vorinostat twice daily on days 1-4;
      vincristine sulfate IV on days 5, 12, 19, and 26; oral prednisone twice daily on days 5-33;
      doxorubicin hydrochloride IV over 15 minutes and cytarabine intrathecally (IT) on day 5;
      pegaspargase IV or intramuscularly on days 6, 12, 19, and 26; and methotrexate* IT on days 12
      and 33. Patients with Philadelphia chromosome-positive disease may also receive oral imatinib
      mesylate once daily on days 5-33.

      NOTE: *Patients with central nervous system (CNS)-positive disease also receive methotrexate
      IT on days 19 and 26.

      Patients undergo blood and bone marrow sample collection at baseline, on day 5, Day 19 and at
      the end of study treatment for correlative laboratory studies.

      After completion of study treatment, patients are followed for 60 days.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow accrual
  </why_stopped>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response to Treatment</measure>
    <time_frame>Day 33</time_frame>
    <description>Response includes both complete remission (defined as &lt;5% leukemic blasts in the bone marrow) and partial remission (defined as a greater than 35% reduction in the bone marrow leukemia blast percentage at day 33)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Level of Methylation</measure>
    <time_frame>Day 0</time_frame>
    <description>the percentage of methylated DNA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of Methylation</measure>
    <time_frame>Day 5</time_frame>
    <description>the percentage of methylated DNA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of Methylation</measure>
    <time_frame>Day 33</time_frame>
    <description>the percentage of methylated DNA</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Decitabine / Vorinostat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is a therapeutic trial investigating the combination of decitabine 15 mg/m2 and vorinostat 230 mg/m2 (maximum daily dose not to exceed 400 mg) in relapsed/refractory ALL/LL patients prior to induction chemotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine</intervention_name>
    <description>At baseline when peripheral blood draw and bone marrow aspirate performed.
*Intrathecal Cytarabine administered dependent upon age - ranging from 30 mg to 70 mg.</description>
    <arm_group_label>Decitabine / Vorinostat</arm_group_label>
    <other_name>cytosine arabinoside</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>decitabine</intervention_name>
    <description>Days 1-4, 15 mg/m^2 intravenously (IV) over 1 hour</description>
    <arm_group_label>Decitabine / Vorinostat</arm_group_label>
    <other_name>Dacogen(R)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
    <description>Day 5, 60 mg/m^2 intravenously (IV) over 15 minutes</description>
    <arm_group_label>Decitabine / Vorinostat</arm_group_label>
    <other_name>Doxorubicin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>imatinib mesylate</intervention_name>
    <description>340 mg/m2 by mouth every day (rounded to the nearest 100 mg) for age &lt;18 years and 400 mg orally every day for &gt;18 years on Days 5-33.</description>
    <arm_group_label>Decitabine / Vorinostat</arm_group_label>
    <other_name>Gleevec(R)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
    <description>**Intrathecal Methotrexate administered dependent upon age - ranging from 8 mg to 15 mg.</description>
    <arm_group_label>Decitabine / Vorinostat</arm_group_label>
    <other_name>MTX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pegaspargase</intervention_name>
    <description>2,500 IU/m2 IM or IV q week (days 6, 12, 19, 26)</description>
    <arm_group_label>Decitabine / Vorinostat</arm_group_label>
    <other_name>PEG asparaginase</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisone</intervention_name>
    <description>40mg/m2/day divided BID (days 5 - 33)</description>
    <arm_group_label>Decitabine / Vorinostat</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine sulfate</intervention_name>
    <description>1.5mg/m2 (max 2 mg) iv push q week (days 5, 12, 19, 26)</description>
    <arm_group_label>Decitabine / Vorinostat</arm_group_label>
    <other_name>Oncovin(R)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vorinostat</intervention_name>
    <description>Days 1-4, (230 mg/m2)orally divided twice a day (max dose 400 mg daily)</description>
    <arm_group_label>Decitabine / Vorinostat</arm_group_label>
    <other_name>suberoylanilide hydroxamic acid (SAHA)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of lymphoblastic lymphoma or acute lymphoblastic leukemia with ≥ 5% blasts
             in the bone marrow (M2/M3) (with or without extramedullary disease) that meets 1 of
             the following criteria:

               -  Refractory disease/induction failure (failure to achieve initial remission after
                  2 lines of induction therapy)

               -  Relapsed disease (in first relapse or higher)

          -  Central nervous system (CNS)-positive disease allowed

          -  Karnofsky performance status (PS) 50-100% (for patients ≥ 16 years of age) OR Lansky
             PS 50-100% (for patients &lt; 16 years of age)

          -  Life expectancy ≥ 8 weeks

          -  Creatinine clearance ≥ 70 mL/min OR maximum serum creatinine based on age/gender as
             follows:

               -  0.4 mg/dL (for patients 1 to 5 months of age)

               -  0.5 mg/dL (for patients 6 to 11 months of age)

               -  0.6 mg/dL (for patients 1 year of age)

               -  0.8 mg/dL (for patients 2 to 5 years of age)

               -  1.0 mg/dL (for patients 6 to 9 years of age)

               -  1.2 mg/dL (for patients 10 to 12 years of age)

               -  1.5 mg/dL (males) or 1.4 mg/dL (females) (for patients 13 to 15 years of age)

               -  1.7 mg/dL (males) or 1.4 mg/dL (females) (for patients ≥ 16 years of age)

          -  ALT &lt; 5 times upper limit of normal (ULN)

          -  Total bilirubin ≤ 1.5 times ULN for age

          -  LVEF ≥ 40% by ECHO/MUGA scan

          -  Shortening fraction &gt; 29% by ECHO/MUGA scan

          -  Able to swallow capsules

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception during and for 2 months after
             completion of study treatment

          -  No untreated positive blood cultures or progressive infections as assessed by
             radiographic studies

          -  No known allergy to any of the agents or their ingredients used in this study

               -  Patients with clinically significant prior allergies to pegaspargase may be
                  treated with asparaginase-Erwinia, if available

          -  Patients who cannot receive asparaginase on this study (e.g., due to prior
             pancreatitis, stroke, or other toxicity) are eligible provided they meet all other
             inclusion/exclusion criteria

          -  Recovered from prior therapy (defined as CTCAE v3.0 toxicity ≤ grade 1)

          -  More than 3 weeks since prior chemotherapy for cancer other than hydroxyurea for
             patients with WBC &gt; 10,000/mm³

          -  At least 7 days since prior hematopoietic growth factors (14 days for pegfilgrastim)

          -  At least 1 month since prior biologic therapy, such as monoclonal antibodies

          -  At least 3 months since prior hematopoietic stem cell transplantation

        Exclusion Criteria:

          -  Evidence of graft-versus-host disease

          -  Concurrent valproic acid

          -  Concurrent coumadin/warfarin other than a short course administered in a prophylactic
             setting
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael J. Burke, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Masonic Cancer Center, University of Minnesota</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Minnesota Amplatz Children's Hospital</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 15, 2009</study_first_submitted>
  <study_first_submitted_qc>April 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 16, 2009</study_first_posted>
  <results_first_submitted>April 10, 2015</results_first_submitted>
  <results_first_submitted_qc>September 8, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 28, 2016</results_first_posted>
  <last_update_submitted>December 3, 2017</last_update_submitted>
  <last_update_submitted_qc>December 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent adult lymphoblastic lymphoma</keyword>
  <keyword>recurrent childhood lymphoblastic lymphoma</keyword>
  <keyword>recurrent adult acute lymphoblastic leukemia</keyword>
  <keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Decitabine</mesh_term>
    <mesh_term>Vorinostat</mesh_term>
    <mesh_term>Pegaspargase</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Azacitidine</mesh_term>
    <mesh_term>Imatinib Mesylate</mesh_term>
    <mesh_term>Asparaginase</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Decitabine / Vorinostat</title>
          <description>This is a therapeutic trial investigating the combination of decitabine 15 mg/m2 and vorinostat 230 mg/m2 (maximum daily dose not to exceed 400 mg) in relapsed/refractory ALL/LL patients prior to induction chemotherapy.
cytarabine: At baseline when peripheral blood draw and bone marrow aspirate performed.
*Intrathecal Cytarabine administered dependent upon age - ranging from 30 mg to 70 mg.
decitabine: Days 1-4, 15 mg/m^2 intravenously (IV) over 1 hour
doxorubicin hydrochloride: Day 5, 60 mg/m^2 intravenously (IV) over 15 minutes
imatinib mesylate: 340 mg/m2 by mouth every day (rounded to the nearest 100 mg) for age &lt;18 years and 400 mg orally every day for &gt;18 years on Days 5-33.
methotrexate: **Intrathecal Methotrexate administered dependent upon age - ranging from 8 mg to 15 mg.
pegaspargase: 2,500 IU/m2 IM or IV q week (days 6, 12, 19, 26)
prednisone: 40mg/m2/day divided BID (days 5 – 33)
vincristine sulfate: 1.5mg/m2 (max 2 mg) iv push q week (days 5, 12,</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Decitabine / Vorinostat</title>
          <description>This is a therapeutic trial investigating the combination of decitabine 15 mg/m2 and vorinostat 230 mg/m2 (maximum daily dose not to exceed 400 mg) in relapsed/refractory ALL/LL patients prior to induction chemotherapy.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16" lower_limit="3" upper_limit="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Response to Treatment</title>
        <description>Response includes both complete remission (defined as &lt;5% leukemic blasts in the bone marrow) and partial remission (defined as a greater than 35% reduction in the bone marrow leukemia blast percentage at day 33)</description>
        <time_frame>Day 33</time_frame>
        <population>The following participants were removed from the analysis: two patients had an early death; one patient had early disease progression; one patient was found to have nervous system involvement on day 5 of therapy; and one patient stopped study therapy due to toxicities.</population>
        <group_list>
          <group group_id="O1">
            <title>Decitabine / Vorinostat</title>
            <description>This is a therapeutic trial investigating the combination of decitabine 15 mg/m2 and vorinostat 230 mg/m2 (maximum daily dose not to exceed 400 mg) in relapsed/refractory ALL/LL patients prior to induction chemotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Response to Treatment</title>
          <description>Response includes both complete remission (defined as &lt;5% leukemic blasts in the bone marrow) and partial remission (defined as a greater than 35% reduction in the bone marrow leukemia blast percentage at day 33)</description>
          <population>The following participants were removed from the analysis: two patients had an early death; one patient had early disease progression; one patient was found to have nervous system involvement on day 5 of therapy; and one patient stopped study therapy due to toxicities.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Level of Methylation</title>
        <description>the percentage of methylated DNA</description>
        <time_frame>Day 0</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Decitabine / Vorinostat</title>
            <description>This is a therapeutic trial investigating the combination of decitabine 15 mg/m2 and vorinostat 230 mg/m2 (maximum daily dose not to exceed 400 mg) in relapsed/refractory ALL/LL patients prior to induction chemotherapy.
cytarabine: At baseline when peripheral blood draw and bone marrow aspirate performed.
*Intrathecal Cytarabine administered dependent upon age - ranging from 30 mg to 70 mg.
decitabine: Days 1-4, 15 mg/m^2 intravenously (IV) over 1 hour
doxorubicin hydrochloride: Day 5, 60 mg/m^2 intravenously (IV) over 15 minutes
imatinib mesylate: 340 mg/m2 by mouth every day (rounded to the nearest 100 mg) for age &lt;18 years and 400 mg orally every day for &gt;18 years on Days 5-33.
methotrexate: **Intrathecal Methotrexate administered dependent upon age - ranging from 8 mg to 15 mg.
pegaspargase: 2,500 IU/m2 IM or IV q week (days 6, 12, 19, 26)
prednisone: 40mg/m2/day divided BID (days 5 – 33)
vincristine sulfate: 1.5mg/m2 (max 2 mg) iv push q week (days 5, 12,</description>
          </group>
        </group_list>
        <measure>
          <title>Level of Methylation</title>
          <description>the percentage of methylated DNA</description>
          <units>percentage of DNA</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.98" spread="1.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Level of Methylation</title>
        <description>the percentage of methylated DNA</description>
        <time_frame>Day 5</time_frame>
        <population>The following participants were removed from the analysis: two patients had an early death; one patient had early disease progression; one patient was found to have nervous system involvement on day 5 of therapy; and one patient stopped study therapy due to toxicities.</population>
        <group_list>
          <group group_id="O1">
            <title>Decitabine / Vorinostat</title>
            <description>This is a therapeutic trial investigating the combination of decitabine 15 mg/m2 and vorinostat 230 mg/m2 (maximum daily dose not to exceed 400 mg) in relapsed/refractory ALL/LL patients prior to induction chemotherapy.
cytarabine: At baseline when peripheral blood draw and bone marrow aspirate performed.
*Intrathecal Cytarabine administered dependent upon age - ranging from 30 mg to 70 mg.
decitabine: Days 1-4, 15 mg/m^2 intravenously (IV) over 1 hour
doxorubicin hydrochloride: Day 5, 60 mg/m^2 intravenously (IV) over 15 minutes
imatinib mesylate: 340 mg/m2 by mouth every day (rounded to the nearest 100 mg) for age &lt;18 years and 400 mg orally every day for &gt;18 years on Days 5-33.
methotrexate: **Intrathecal Methotrexate administered dependent upon age - ranging from 8 mg to 15 mg.
pegaspargase: 2,500 IU/m2 IM or IV q week (days 6, 12, 19, 26)
prednisone: 40mg/m2/day divided BID (days 5 – 33)
vincristine sulfate: 1.5mg/m2 (max 2 mg) iv push q week (days 5, 12,</description>
          </group>
        </group_list>
        <measure>
          <title>Level of Methylation</title>
          <description>the percentage of methylated DNA</description>
          <population>The following participants were removed from the analysis: two patients had an early death; one patient had early disease progression; one patient was found to have nervous system involvement on day 5 of therapy; and one patient stopped study therapy due to toxicities.</population>
          <units>percentage of DNA</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.82" spread="3.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Level of Methylation</title>
        <description>the percentage of methylated DNA</description>
        <time_frame>Day 33</time_frame>
        <population>The following participants were removed from the analysis: two patients had an early death; one patient had early disease progression; one patient was found to have nervous system involvement on day 5 of therapy; and one patient stopped study therapy due to toxicities.</population>
        <group_list>
          <group group_id="O1">
            <title>Decitabine / Vorinostat</title>
            <description>This is a therapeutic trial investigating the combination of decitabine 15 mg/m2 and vorinostat 230 mg/m2 (maximum daily dose not to exceed 400 mg) in relapsed/refractory ALL/LL patients prior to induction chemotherapy.
cytarabine: At baseline when peripheral blood draw and bone marrow aspirate performed.
*Intrathecal Cytarabine administered dependent upon age - ranging from 30 mg to 70 mg.
decitabine: Days 1-4, 15 mg/m^2 intravenously (IV) over 1 hour
doxorubicin hydrochloride: Day 5, 60 mg/m^2 intravenously (IV) over 15 minutes
imatinib mesylate: 340 mg/m2 by mouth every day (rounded to the nearest 100 mg) for age &lt;18 years and 400 mg orally every day for &gt;18 years on Days 5-33.
methotrexate: **Intrathecal Methotrexate administered dependent upon age - ranging from 8 mg to 15 mg.
pegaspargase: 2,500 IU/m2 IM or IV q week (days 6, 12, 19, 26)
prednisone: 40mg/m2/day divided BID (days 5 – 33)
vincristine sulfate: 1.5mg/m2 (max 2 mg) iv push q week (days 5, 12,</description>
          </group>
        </group_list>
        <measure>
          <title>Level of Methylation</title>
          <description>the percentage of methylated DNA</description>
          <population>The following participants were removed from the analysis: two patients had an early death; one patient had early disease progression; one patient was found to have nervous system involvement on day 5 of therapy; and one patient stopped study therapy due to toxicities.</population>
          <units>percentage of DNA</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.1" spread="1.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Decitabine / Vorinostat</title>
          <description>This is a therapeutic trial investigating the combination of decitabine 15 mg/m2 and vorinostat 230 mg/m2 (maximum daily dose not to exceed 400 mg) in relapsed/refractory ALL/LL patients prior to induction chemotherapy.
cytarabine: At baseline when peripheral blood draw and bone marrow aspirate performed.
*Intrathecal Cytarabine administered dependent upon age - ranging from 30 mg to 70 mg.
decitabine: Days 1-4, 15 mg/m^2 intravenously (IV) over 1 hour
doxorubicin hydrochloride: Day 5, 60 mg/m^2 intravenously (IV) over 15 minutes
imatinib mesylate: 340 mg/m2 by mouth every day (rounded to the nearest 100 mg) for age &lt;18 years and 400 mg orally every day for &gt;18 years on Days 5-33.
methotrexate: **Intrathecal Methotrexate administered dependent upon age - ranging from 8 mg to 15 mg.
pegaspargase: 2,500 IU/m2 IM or IV q week (days 6, 12, 19, 26)
prednisone: 40mg/m2/day divided BID (days 5 – 33)
vincristine sulfate: 1.5mg/m2 (max 2 mg) iv push q week (days 5, 12)</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pain, abdominal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection, blood</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Lipase elevated</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertriglyceridemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hypercholesteremia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain, generalized body</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Decreased respiratory rate</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hypoxia - acute respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhage, bladder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Leukocytes decreased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Platelets count decreased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Bone marrow cellularity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Leukocytes</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Neutrophils</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>ANC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Ventricular arrythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Systolic murmur</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenal insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Photophobia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Blurred vision</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Fluid retention, ascites</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Lower molar pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Edema, lower extremity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Edema, upper extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Generalised body aches</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection, meningitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Fungal infection, lung</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Infection, soft tissue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Infection, neutopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Infection, positive blood culture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Pain uncontrolled</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pain, epigastric</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pain, headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pain, pedal bilateral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pain, leg bilateral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pain, stomach</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pain, left chest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pain, low back/leg</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Lower lip swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pain, NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Weight gain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Creatinine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Lipase elevated</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>ALT increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Fibrinogen increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Amylase</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Lipase</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>AST increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>AST</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypermagnesemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hyperchloremia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Albumin</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Calcium</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Glucose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Uric acid increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Calcium decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hyperphosphatemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Calcium increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Obesity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Knee pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hip pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Headaches</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hemiparesis, right side</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mood alteration, NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic kidney disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Sleep apnea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pulmonary infiltrate</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hand foot reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Demi Erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Ulceration, decubitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Michael Burke, MD</name_or_title>
      <organization>University of Minnesota, Pediatric Hematology Dept.</organization>
      <phone>612.672.7422</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

